Neumora Therapeutics, Inc. Common Stock

NMRA

NASDAQ

Healthcare

Biotechnology

Watertown, DE, US110 employeesneumoratx.com

$2.00

-0.10(-4.55%)

Mkt Cap $333M

$0.62

$3.59

52-Week Range

At a Glance

AI-generated

Operating Income was -$241.2M (8.5%) Net Income was -$236.9M (2.8%) Eps was $-1.45 (5.2%)

8-K

Neumora Therapeutics reported Q4 2025 net loss of $59.4 million and full-year 2025 net loss of $236.9 million, with cash of $182.5 million funding operations into Q3 2027.

$333M

Market Cap

—

Revenue

-$244M

Net Income

Employees110

Fundamentals

How The Business Makes Money

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Financial Results

Mar 29, 2026

of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18

Regulation FD

Feb 10, 2026

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act

Regulation FD

Jan 11, 2026

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act

Other Event

Jan 4, 2026

Other Events. On January 5, 2026, Neumora Therapeutics, Inc. (the “Company”) issued press releases announcing positive results from its Phase 1b signal-seeking

Peer Companies

Company	Price	Change	Market Cap	P/E
ALMSAlumis Inc. Common Stock	$23.42	+3.04%	$2.9B	-10.1
RAPTRAPT Therapeutics, Inc.	$58.01	+0.00%	$959M	-14.8
OMEROmeros Corporation	$10.94	-9.44%	$776M	-5.8
LXRXLexicon Pharmaceuticals, ...	$1.59	-2.74%	$676M	-11.8
PRTAProthena Corporation plc	$9.82	-2.09%	$529M	-1.9
FDMT4D Molecular Therapeutics...	$9.49	-3.85%	$484M	-3.8
ADCTADC Therapeutics S.A.	$3.80	+0.03%	$483M	-4.3
FULCFulcrum Therapeutics, Inc...	$8.06	+7.75%	$436M	-5.8

Analyst View

Company Profile

CIK0001885522

ISINUS6409791000

CUSIP640979100

Phone857 760 0900

Address490 Arsenal Way, Watertown, DE, 02472, US

SEC EDGAR